Sancilio & Company Revenue
Pharmaceutical Manufacturing • 
Stuart, Florida, United States • 21-50 Employees
Sancilio & Company revenue & valuation
| Annual revenue | $7,835,531 |
| Revenue per employee | $183,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $25,100,000 |
| Total funding | $20,000,000 |
Key Contacts at Sancilio & Company
Gurpreet Singh
Global Director Project Management Cmc & Clinical Trails
Rizwan Kazmi
Senior Director, R & D
Trevor Gianaris
Director Of Finance & Operations
Ahmed Daak
Director Clinical Research
Baul Nana Naim
Senior Director
Company overview
| Headquarters | 7851 SW Ellipse Way, Stuart, Florida 34997, US |
| Phone number | +15618911737 |
| Website | |
| NAICS | 3254 |
| Keywords | Research & Development, Omega-3, Advanced Lipid Technologies, Omega-3 Research & Training, Ultra Pure Omega-3 |
| Founded | 2019 |
| Employees | 21-50 |
| Socials |
Sancilio & Company Email Formats
Sancilio & Company uses 2 email formats. The most common is {first name} (e.g., john@secureserver.net), used 60% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name} | john@secureserver.net | 60% |
{first name}{last name} | johndoe@secureserver.net | 40% |
About Sancilio & Company
Incorporated in 2019, Sancilio & Company is wholly owned by Dr. and Mrs. Sancilio. Offices of the firm are in Stuart, Florida. Sancilio & Company has two lines of businesses: Clearway Global, LLC operates as a pharmaceutical research & development service through a network of associates that span the entire development process from discovery through clinical trials and Omega Blu by Sancilio, a company which sells high quality nutritional products. At present, Sancilio & Company is involved in the management of several NDA programs at various stages of development. We are actively engaged in sourcing API from global manufacturers, designing regulatory strategies for new and existing drugs, project managing the creation of CMC packages for NDA submissions and developing clinical research programs for eventual submission to the US FDA. More recently, we've began working with global CROs to design pathways to approval external to the United States. Hence, we are meeting with regulators in Japan and elsewhere to design parallel international regulatory strategies. We have been operating our contract development business as "Clearway Global" for the past 2 years and recently incorporated Sancilio & Company, Inc. to manage the internal research programs and product offerings. The former company using a similar name (Sancilio Pharmaceutical Company, Inc.) was founded by the Sancilio family in 2005. Following a change of control in 2017, the Sancilio family departed and operations and management was reorganized. Eventually assets of the former company were sold to several acquirers and remaining operations were terminated. The new Sancilio & Company, is sponsoring its own development work in fatty acid research, improved bio-availability of lipids and applications of essential fatty acids to treat disease.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Sancilio & Company has 19 employees across 6 departments.
Departments
Number of employees
Canada
United Kingdom
Singapore
CzechiaFrequently asked questions
4.8
40,000 users
